Identification of Comorbid Genes of Psoriasis and Coronary Artery Disease Using Ustekinumab with Astragalus

Background: Systemic inflammation leading to coronary atherosclerotic heart disease (CAD) increases the risk for Psoriasis (PSO). Despite progress in diagnostic and therapeutic strategies for CAD, it is hard to identify many patients in time, and their lives are threatened. Objectives: To explore the comorbidity genes of psoriasis (PSO) and coronary artery disease (CAD) under the intervention of Ustekinumab combined with Astragalus, and to provide new ideas for clinical treatment. Materials and Methods: The PSO datasets (GSE13355, GSE14905) and CAD datasets (GSE113079, GSE23561) were obtained from the Gene Expression Omnibus database. Key genes were screened through differential expression analysis, weighted gene co-expression network analysis (WGCNA), gene enrichment analysis, protein–protein interaction (PPI) network construction, and immune infiltration analysis. Results: A total of 2,412 PSO differential genes and 4,443 CAD differential genes were identified. WGCNA analysis yielded 8,809 PSO-related module genes and 8,389 CAD-related module genes. Cross-analysis identified 186 genes with consistent expression trends. Eventually, aurora kinase B (AURKB), C-X-C motif chemokine ligand 11 (CXCL11), late cornified envelope 3D (LCE3D), tumor necrosis factor ligand superfamily member 10 (TNFSF10), and CD247 were determined as key comorbidity genes, enriched in the proteasome and olfactory conduction pathways. Conclusion: AURKB, CXCL11, LCE3D, TNFSF10, and CD247 were indicated as comorbid genes for PSO and CAD, and they therefore might be involved in the progression of these diseases.